Shareholder Votes

HighPeak Energy, Inc. shareholders approved Approval of the frequency of future say-on-pay votes at the 2026-06-02 meeting.

“One Year Two Years Three Years Votes Abstained Broker Non-Votes 87,519,758 78,545 241,253 72,128 11,238,238”

HighPeak Energy, Inc. shareholders approved Approval of compensation paid to the Company’s Named Executive Officers (say-on-pay) at the 2026-06-02 meeting.

“Votes For Votes Against Votes Abstained Broker Non-Votes 82,986,947 4,884,646 40,091 11,238,238”

HighPeak Energy, Inc. shareholders approved Election of three Class C director nominees at the 2026-06-02 meeting.

“Votes For Votes Withheld Broker Non-Votes Jason A. Edgeworth 83,836,912 4,074,772 11,238,238 Larry C. Oldham 87,753,294 158,390 11,238,238 Daniel Silver 87,081,310 830,374 11,238,238”

ADC Therapeutics SA shareholders approved Approving amendments to articles 4a, 4b and 4c of the articles of association to increase the Company’s capital range (article 4a), conditional share capital for employee participation (article 4b) and conditional share capital for financing, acquisitions and other purposes (article 4c) as well as t at the 2026-06-01 meeting.

“Proposal #12 : Approving amendments to articles 4a, 4b and 4c of the articles of association to increase the Company’s capital range (article 4a), conditional share capital for employee participation (article 4b) and conditional share capital for financing, acquisitions and other purposes (article 4c) as well as the introduction of article 4d regarding a conditional share capital based on the capital range The shareholders approved (i) amendments to article 4a paragraph 1 of the articles of association to increase the Company’s capital range from CHF 8,375,974.48 (lower limit) to CHF 12,354,128.80 (upper limit) to CHF 10,378,109.12 (lower limit) to CHF 15,567,163.68 (upper limit) (Proposal #12a), (ii) amendments to article 4b paragraph 1 of the articles of association to increase the Company’s conditional share capital for employee participation from 9,887,629 common shares (CHF 791,010.32) to 16,836,253 common shares (CHF 1,346,900.24) (Proposal #12b)”

ADC Therapeutics SA shareholders approved Approving an amendment to increase the number of shares authorized under the 2019 Equity Incentive Plan at the 2026-06-01 meeting.

“Proposal #11 : Approving an amendment to increase the number of shares authorized under the 2019 Equity Incentive Plan The shareholders approved an amendment to increase the number of shares authorized under the 2019 Equity Incentive Plan. The voting results were as follows: FOR AGAINST ABSTAIN BROKER NON-VOTES 46,624,648 18,904,924 3,817,798 14,253,584”

ADC Therapeutics SA shareholders approved Approving, on an advisory basis under U.S. law, the compensation paid to the named executive officers at the 2026-06-01 meeting.

“Proposal #10 : Approving, on an advisory basis under U.S. law, the compensation paid to the named executive officers The shareholders approved, on an advisory basis under U.S. law, the compensation of the Company’s named executive officers, as disclosed in “Executive Compensation” and the related compensation tables and narrative disclosure in the proxy statement. The voting results were as follows: FOR AGAINST ABSTAIN BROKER NON-VOTES 64,172,306 1,271,205 3,903,859 14,253,584”

ADC Therapeutics SA shareholders approved Approving, on a binding basis under Swiss law, the compensation of the board of directors and the executive committee at the 2026-06-01 meeting.

“Proposal #9 : Approving, on a binding basis under Swiss law, the compensation of the board of directors and the executive committee The shareholders approved, on a binding basis under Swiss law, that (i) the maximum aggregate amount of compensation for the members of the board of directors for the period between the Annual Meeting and the 2027 annual general meeting of shareholders be set at $2,500,000 (Proposal #9a), (ii) the maximum aggregate amount of fixed compensation for the members of the executive committee for the year ending December 31, 2027 be set at $2,600,000 (Proposal #9b) and (iii) the maximum aggregate amount of variable compensation for the members of the executive committee for the year ending December 31, 2026 be set at $5,500,000 (Proposal #9c). The voting results were as follows: PROPOSAL FOR AGAINST ABSTAIN BROKER NON-VOTES #9a 48,456,972 16,977,874 3,912,524 14,253,584 #9b 64,981,047 439,267 3,927,056 14,253,584 #9c 64,541,036 883,352 3,922,982 14,253,584”

ADC Therapeutics SA shareholders approved Reelecting the auditors at the 2026-06-01 meeting.

“Proposal #8 : Reelecting the auditors The shareholders reelected PricewaterhouseCoopers SA as the statutory auditor and independent registered public accounting firm for the year ending December 31, 2026. The voting results were as follows: FOR AGAINST ABSTAIN BROKER NON-VOTES 79,747,180 31,325 3,822,449 —”

ADC Therapeutics SA shareholders approved Reelecting the Independent Proxy at the 2026-06-01 meeting.

“Proposal #7 : Reelecting the Independent Proxy The shareholders reelected PHC Notaires, in Lausanne, Switzerland, as the Independent Proxy for a one-year term, beginning as of the Annual Meeting and ending at the closing of the 2027 annual general meeting of shareholders. The voting results were as follows: FOR AGAINST ABSTAIN BROKER NON-VOTES 79,756,534 17,712 3,826,708 —”

ADC Therapeutics SA shareholders approved Reelecting compensation committee members at the 2026-06-01 meeting.

“Proposal #6 : Reelecting compensation committee members The shareholders reelected the following members of the compensation committee for a one-year term, beginning as of the Annual Meeting and ending at the closing of the 2027 annual general meeting of shareholders. The voting results were as follows: NAME FOR AGAINST ABSTAIN BROKER NON-VOTES Robert Azelby 65,136,589 388,421 3,822,360 14,253,584 Peter Hug 65,014,833 469,178 3,863,359 14,253,584 Victor Sandor 65,145,109 380,752 3,821,509 14,253,584”

ADC Therapeutics SA shareholders approved Reelecting directors at the 2026-06-01 meeting.

“Proposal #5 : Reelecting directors The shareholders reelected the following directors for a one-year term, beginning as of the Annual Meeting and ending at the closing of the 2027 annual general meeting of shareholders. The voting results were as follows: NAME FOR AGAINST ABSTAIN BROKER NON-VOTES Ron Squarer 65,109,377 416,194 3,821,799 14,253,584 Robert Azelby 65,094,726 429,835 3,822,809 14,253,584 Jean-Pierre Bizzari 63,631,611 1,852,731 3,863,025 14,253,587 Timothy Coughlin 65,198,947 327,049 3,821,374 14,253,584 Peter Hug 64,927,601 556,545 3,863,224 14,253,584 Ameet Mallik 65,133,390 387,036 3,826,944 14,253,584 Viviane Monges 64,918,973 556,772 3,871,625 14,253,584 Tyrell Rivers 64,796,462 729,534 3,821,374 14,253,584 Victor Sandor 65,151,213 373,932 3,822,225 14,253,584”

ADC Therapeutics SA shareholders approved Approving the appropriation of the financial results at the 2026-06-01 meeting.

“Proposal #4 : Approving the appropriation of the financial results The shareholders approved that the net loss for the year ended December 31, 2025 be carried forward. The voting results were as follows: FOR AGAINST ABSTAIN BROKER NON-VOTES 79,774,946 8,511 3,817,497 —”

ADC Therapeutics SA shareholders approved Discharging the members of the board of directors and the executive committee from liability at the 2026-06-01 meeting.

“Proposal #3 : Discharging the members of the board of directors and the executive committee from liability The shareholders approved that the members of the board of directors and the executive committee be discharged from liability for the year ended December 31, 2025. The voting results were as follows: FOR AGAINST ABSTAIN BROKER NON-VOTES 63,695,590 86,523 3,966,182 14,253,584”

ADC Therapeutics SA shareholders approved Approving, on an advisory basis under Swiss law, the compensation report at the 2026-06-01 meeting.

“Proposal #2 : Approving, on an advisory basis under Swiss law, the compensation report The shareholders approved, in a non-binding advisory vote, the compensation report for the year ended December 31, 2025. The voting results were as follows: FOR AGAINST ABSTAIN BROKER NON-VOTES 64,289,299 1,242,782 3,815,289 14,253,584”

ADC Therapeutics SA shareholders approved Approving the management report, annual financial statements and consolidated financial statements at the 2026-06-01 meeting.

“Proposal #1 : Approving the management report, annual financial statements and consolidated financial statements The shareholders approved the management report, the annual financial statements and the consolidated financial statements for the year ended December 31, 2025 and acknowledged the auditors’ report for the year ended December 31, 2025. The voting results were as follows: FOR AGAINST ABSTAIN BROKER NON-VOTES 79,705,454 5,910 3,889,590 —”

HARVARD BIOSCIENCE INC shareholders approved Approval of the Amended and Restated 2021 Incentive Plan at the 2026-06-02 meeting.

“Proposal 5 – Approval of the Amended and Restated 2021 Incentive Plan The Company’s stockholders approved the Amended and Restated 2021 Incentive Plan to increase the number of authorized shares of common stock available for issuance thereunder, as follows: Votes For Votes Against Votes Abstained Broker Non-Votes 1,131,261 680,030 17,700 970,538”

HARVARD BIOSCIENCE INC shareholders approved Approval of the Amendment to the Harvard Bioscience, Inc. Employee Stock Purchase Plan at the 2026-06-02 meeting.

“Proposal 4 – Approval of the Amendment to the Harvard Bioscience, Inc. Employee Stock Purchase Plan The Company’s stockholders approved the amendment to the Harvard Bioscience, Inc. Employee Stock Purchase Plan to increase the number of authorized shares of common stock available for issuance thereunder, as follows: Votes For Votes Against Votes Abstained Broker Non-Votes 1,705,565 90,905 32,521 970,538”

HARVARD BIOSCIENCE INC shareholders approved Approval, by Non-Binding Advisory Vote, of the Compensation of the Company’s Named Executive Officers at the 2026-06-02 meeting.

“Proposal 3 –Approval, by Non-Binding Advisory Vote, of the Compensation of the Company’s Named Executive Officers The Company’s stockholders approved the compensation of the Company’s named executive officers by a non-binding advisory vote, as follows: Votes For Votes Against Votes Abstained Broker Non-Votes 1,768,695 57,111 3,185 970,538”

HARVARD BIOSCIENCE INC shareholders approved Ratification of the Appointment of Grant Thornton LLP at the 2026-06-02 meeting.

“Proposal 2 –Ratification of the Appointment of Grant Thornton LLP The Company’s stockholders ratified the appointment of Grant Thornton LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, as follows: Votes For Votes Against Votes Abstained 2,781,705 13,975 3,849”

HARVARD BIOSCIENCE INC shareholders approved Election of two Class II Directors at the 2026-06-02 meeting.

“On June 2, 2026, the Company held its Annual Meeting, at which the Company’s stockholders voted on five proposals that are described in detail in the Definitive Proxy Statement. The voting results for each of the proposals are reported below. Proposal 1 - Election of Directors The Company’s stockholders elected two Class II Directors for three-year terms, such terms to continue until the annual meeting of stockholders in 2029 and until such Directors’ successors are duly elected and qualified or until his or her earlier resignation or removal: Name Votes For Votes Withheld Broker Non-Votes John Duke 1,800,288 28,703 970,538 Katherine A. Eade 1,680,982 148,009 970,538”

Forte Biosciences, Inc. shareholders approved Approval of the Amended and Restated 2021 Equity Incentive Plan at the 2026-05-29 meeting.

“4. Approval of the Amended and Restated 2021 Equity Incentive Plan . The Company’s stockholders approved the A&R 2021 Equity Incentive Plan. The votes regarding the proposal were as follows: Votes For Votes Against Abstentions Broker Non-Votes 11,911,879 3,997,050 351,042 1,506,063”

Forte Biosciences, Inc. shareholders approved Advisory Vote on Executive Compensation at the 2026-05-29 meeting.

“3. Advisory Vote on Executive Compensation. The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers for the fiscal year ended December 31, 2025. The votes regarding the proposal were as follows: Votes For Votes Against Abstentions Broker Non-Votes 12,143,153 3,764,729 352,089 1,506,063”

Forte Biosciences, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2026-05-29 meeting.

“2. Ratification of Appointment of Independent Registered Public Accounting Firm. The appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified based on the following results of voting: Votes For Votes Against Abstentions Broker Non-Votes 17,722,893 3,182 39,959 0”

Forte Biosciences, Inc. shareholders approved Election of Class III Directors at the 2026-05-29 meeting.

“1. Election of Class III Directors. The following nominees were elected to serve as Class III directors, each to hold office until the Company’s 2029 annual meeting of stockholders or until his respective successor has been duly elected and qualified or his or her earlier resignation or removal: Nominee Votes For Votes Withheld Broker Non-Votes Steven Kornfeld 12,286,043 3,973,928 1,506,063 Scott Brun, M.D. 12,958,889 3,301,082 1,506,063 Paul A. Wagner, Ph.D. 16,027,110 232,861 1,506,063”

Tyra Biosciences, Inc. shareholders approved Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. at the 2026-05-28 meeting.

“2. The ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The appointment was ratified by the votes indicated: For Against Abstain Broker Non-Votes 53,092,820 1,316 3,246 –”

Tyra Biosciences, Inc. shareholders approved Election of three Class II directors to serve for a three-year term expiring at the 2029 Annual Meeting of Stockholders. at the 2026-05-28 meeting.

“1. The election of three directors to serve as Class II directors for a three-year term to expire at the 2029 Annual Meeting of Stockholders. The following three Class II directors were elected by the votes indicated: For Withheld Broker Non-Votes Habib J. Dable 44,242,803 476,602 8,377,977 Susan Moran, M.D., M.S.C.E. 44,529,688 189,717 8,377,977 Robert More 41,013,686 3,705,719 8,377,977”

SAGA COMMUNICATIONS INC shareholders approved Adopt, by a non-binding advisory vote, a resolution approving the compensation of our named executive officers at the 2026-06-01 meeting.

“The proposal to adopt, by a non-binding advisory vote, a resolution approving the compensation of our named executive officers was approved with 3,020,736 votes cast for, 1,760,704 votes cast against, 863,982 broker non-votes and 12,036 abstentions.”

SAGA COMMUNICATIONS INC shareholders approved Ratify appointment of Crowe LLP as independent auditors at the 2026-06-01 meeting.

“The proposal to ratify the appointment by the Board of Directors of Crowe LLP as independent auditors to audit our consolidated financial statements for the fiscal year ending December 31, 2026 was approved with 5,571,362 votes cast for, 24,494 votes cast against and 61,602 abstentions.”

SAGA COMMUNICATIONS INC shareholders approved Election of seven nominees as directors at the 2026-06-01 meeting.

“The seven nominees for election as directors for the ensuing year, and until their successors are elected and qualified, were elected and received the following votes:”

Gogo Inc. shareholders approved Ratification of independent registered public accounting firm at the 2026-05-28 meeting.

“Stockholders ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.”

Gogo Inc. shareholders approved Vote to approve A&R 2024 Plan at the 2026-05-28 meeting.

“Stockholders approved the A&R 2024 Plan.”

Gogo Inc. shareholders approved Advisory vote to approve executive compensation at the 2026-05-28 meeting.

“Stockholders approved the non-binding advisory resolution approving 2025 executive compensation.”

Gogo Inc. shareholders approved Election of Class I Directors at the 2026-05-28 meeting.

“Stockholders elected each of the following Class I directors to serve a three-year term expiring at the Company’s 2029 annual meeting of stockholders or until their successors are duly elected and qualified.”

BUCKLE INC shareholders approved Advisory vote on the frequency of future advisory votes on compensation of Named Executive Officers at the 2026-06-01 meeting.

“Proposal 4 - Advisory vote on the frequency of future advisory votes on compensation of Named Executive Officers 22,869,332 17,898 21,650,173 67,925 2,913,652”

BUCKLE INC shareholders approved Advisory vote on overall compensation for Named Executive Officers at the 2026-06-01 meeting.

“Proposal 3 - Advisory vote on overall compensation for Named Executive Officers 42,971,864 1,516,777 116,687 2,913,652”

BUCKLE INC shareholders approved Ratify the selection of Deloitte & Touche LLP as independent registered public accounting firm at the 2026-06-01 meeting.

“Proposal 2 - Ratify the selection of Deloitte & Touche LLP as independent registered public accounting firm 47,061,960 367,662 89,358 —”

BUCKLE INC shareholders approved Election of Board of Directors at the 2026-06-01 meeting.

“Proposal 1 - Election of Board of Directors: Daniel J. Hirschfeld 44,002,591 — 602,737 2,913,652 Dennis H. Nelson 44,212,070 — 393,258 2,913,652 Thomas B. Heacock 43,417,980 — 1,187,348 2,913,652 Hank M. Bounds 44,376,513 — 228,815 2,913,652 Bill L. Fairfield 42,327,596 — 2,277,732 2,913,652 Bruce L. Hoberman 42,379,175 — 2,226,153 2,913,652 Michael E. Huss 42,796,669 — 1,808,659 2,913,652 Shruti S. Joshi 44,098,534 — 506,794 2,913,652 Angie J. Klein 40,628,671 — 3,976,657 2,913,652 John P. Peetz, III 42,437,517 — 2,167,811 2,913,652 Karen B. Rhoads 31,143,442 — 13,461,886 2,913,652 James E. Shada 42,487,829 — 2,117,499 2,913,652”

Cornerstone Building Brands, Inc. shareholders approved Re-election of directors at the 2026-05-27 meeting.

“On May 27, 2026, Camelot Return Intermediate Holdings, LLC (“Parent”), as the sole stockholder of the Company, acting by written consent in lieu of an annual meeting, re-elected the following individuals as directors of the Company, each to serve effective immediately until the next annual meeting of the Parent or until their successors are duly elected and qualified, or until their earlier death, resignation or removal: Marcia Avedon, Jake Donnelly, Carol Flaton, Wilbert James, Jr., Daniel Janki, John Krenicki, Jr., Timothy O’Brien, Daniel Silvers, Nathan Sleeper, Gunner Smith, Suzanne Stefany, and Tyler Young.”

DUOS TECHNOLOGIES GROUP, INC. shareholders approved To elect Frank D. Recker, Chief Executive Officer of the Company, to serve as a member of the board of directors and to hold office for a one-year term and until his successor is elected and qualified. at the 2026-05-28 meeting.

“Frank D. Recker 13,959,958 2,064,009”

DUOS TECHNOLOGIES GROUP, INC. shareholders approved To ratify the appointment of Salberg & Company, P.A. as our independent certified public accounting firm for the fiscal year ending December 31, 2026. at the 2026-05-28 meeting.

“Votes For Votes Against Abstentions 23,023,580 59,973 320,502”

DUOS TECHNOLOGIES GROUP, INC. shareholders approved To elect five directors to hold office for a one-year term and until each of their successors is elected and qualified. at the 2026-05-28 meeting.

“Votes For Votes With held Charles P. Ferry 17,287,342 378,458 Frank A. Lonegro 12,275,595 5,390,205 Ned Mavrommatis 12,492,813 5,172,987 James Craig Nixon 12,863,671 4,802,129 Brian J. James 17,359,835 305,965”

AppTech Payments Corp. shareholders approved Ratification of dbbmckennon, LLC as independent auditor for fiscal year 2026 at the 2026-05-28 meeting.

“5. The appointment of dbbmckennon, LLC as the Company’s independent registered public accounting firm for fiscal year 2026 was ratified by the shareholders: Votes For Against Abstain Broker Non-Votes 25,837,544 78,756 1,648,545 -”

AppTech Payments Corp. shareholders approved Approval of 2026 AppTech Equity Incentive Plan at the 2026-05-28 meeting.

“4. The shareholders approved the 2026 AppTech Equity Incentive Plan: Votes For Against Abstain Broker Non-Votes 21,612,652 1,749,190 3,628,936 574,067”

AppTech Payments Corp. shareholders approved Advisory vote on frequency of future say-on-pay votes at the 2026-05-28 meeting.

“3. The shareholders indicated, on an advisory basis, the preferred frequency of future stockholder advisory votes on the compensation of the Company’s named executive officers for One Year: One Year Two Years Three Years Abstain Broker Non-Votes 21,868,753 1,049,477 750,181 3,222,397 574,067”

AppTech Payments Corp. shareholders approved Advisory vote on compensation of named executive officers at the 2026-05-28 meeting.

“2. The shareholders approved, on an advisory basis, the compensation of the Company’s named executive officers: Votes For Against Abstain Broker Non-Votes 22,309,168 1,532,022 3,149,588 574,067”

AppTech Payments Corp. shareholders approved Election of Class II directors at the 2026-05-28 meeting.

“1. The shareholders voted to elect each of the two (2) Class II director nominees to serve two-year terms: Director Nominee Votes For Withheld Broker Non-Votes Albert L. Lord 24,278,883 2,711,895 574,067 Thomas J. DeRosa 18,839,757 8,151,021 574,067”

Sensus Healthcare, Inc. shareholders approved Auditor Appointment Ratification at the 2026-05-29 meeting.

“3. Auditor Appointment Ratification . Stockholders ratified the appointment of Carr, Riggs & Ingram, LLC as the Company’s independent registered public accountant for the fiscal year ended December 31, 2026. The tabulation of votes cast was as follows: For Against Abstention 10,738,792 148,466 432,715”

Sensus Healthcare, Inc. shareholders approved Advisory Vote on Executive Compensation at the 2026-05-29 meeting.

“2. Advisory Vote on Executive Compensation . Stockholders approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers for 2025. The tabulation of votes cast was as follows: For Against Abstention Broker Non-Votes 4,740,572 856,128 722,554 5,000,719”

Sensus Healthcare, Inc. shareholders approved Election of Directors at the 2026-05-29 meeting.

“1. Election of Directors . Eric Sachetta and Michael J. Sardano were elected as Class II directors for a three-year term to expire in 2029. Each nominee was an incumbent director, and no other person was nominated. The tabulation of votes cast was as follows: For Against Abstention Broker Non-Votes Eric Sachetta 5,532,247 516,567 270,440 5,000,719 Michael J. Sardano 4,702,852 1,346,063 270,339 5,000,719”

DOLLAR GENERAL CORP shareholders rejected Shareholder proposal to reduce special meeting ownership threshold at the 2026-05-28 meeting.

“A shareholder proposal asking the Board to take the steps necessary to reduce the minimum ownership percentage required to call a special shareholders’ meeting from 25% to 10% was not approved.”